IgD型骨髓瘤的临床特征与结局:英国全国性试验的经验
该研究基于英国3期骨髓瘤试验,比较旧试验(1980-2002年)与近期试验(2002-2016年)中IgD型骨髓瘤患者的临床特征与结局。IgD型骨髓瘤在旧试验中占44/2789(1.6%),在近期试验中占70/5773(1.2%)。近期试验诱导治疗后总缓解率更高(89% vs 43%,P < .0001),中位总生存期更长(48个月;95%CI 35-67个月 vs 22个月;95%CI 16-29个月)。
要点
- IgD型骨髓瘤以男性为主,常伴低水平副蛋白血症(<10g/L)和λ轻链偏好。
- 超高风险细胞遗传学频率在IgD型与其他亚型间相似(4.3% vs 5.3%,P > .99)。
- 近期试验中IgD型骨髓瘤的诱导后总缓解率和中位总生存期均优于旧试验。
核心结论
- 由于更早诊断、新型疗法和改进的支持治疗,IgD型骨髓瘤的生存结局已显著改善,现已与其他骨髓瘤类型相当。
研究设计与样本
- 研究分析了英国3期骨髓瘤试验中的IgD型骨髓瘤患者,按试验时间分为旧试验(1980-2002年)和近期试验(2002-2016年)两组。
- 旧试验组IgD型患者44例,占该组总2789例的1.6%;近期试验组70例,占该组总5773例的1.2%。
主要发现
- IgD型骨髓瘤总体与男性 predominance、低水平副蛋白血症(<10g/L)和λ轻链偏好相关。
- 超高风险细胞遗传学频率在IgD型与其他亚型中相似(4.3% vs 5.3%,P > .99)。
- 旧试验组较近期试验组中位年龄更小(59 vs 63岁,P = .015),但骨病变、诊断时晚期阶段、体能状态差和严重肾损害的发生率更高。
- 旧试验组早期死亡率显著高于近期试验组(20% vs 4%,P = .01)。
- 近期试验组诱导治疗后总缓解率显著高于旧试验组(89% vs 43%,P < .0001),中位总生存期更长(48个月;95%CI 35-67个月 vs 22个月;95%CI 16-29个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunoglobulin D (IgD) myeloma is a subtype often considered to have adverse features and inferior survival, but there is a paucity of data from large clinical studies. We compare the clinical characteristics and outcomes of patients with IgD myeloma from UK phase 3 myeloma trials analyzed in 2 groups: old (1980-2002) and recent (2002-2016) clinical trials, based on the time of adoption of novel myeloma therapies. Patients with IgD myeloma comprised 44 of 2789 (1.6%) and 70 of 5773 (1.2%) of the old and recent trials, respectively. Overall, IgD myeloma was associated with male predominance, low-level paraproteinemia (<10g/L), and λ light chain preference. The frequency of ultra-high-risk cytogenetics was similar in IgD myeloma compared with other subtypes (4.3% vs 5.3%, P > .99). Despite the old trial series being a younger group (median age: 59 vs 63 years, P = .015), there was a higher frequency of bone lesions, advanced stage at diagnosis, worse performance status, and severe renal impairment compared with the recent trials. Furthermore, the early mortality rate was significantly higher for the old trial series (20% vs 4%, P = .01). The overall response rate following induction therapy was significantly higher in the recent trials (89% vs 43%, P < .0001), and this was consistent with improved median overall survival (48 months; 95% confidence interval [CI] 35-67 months vs 22 months; 95% CI, 16-29 months). Survival outcomes for IgD myeloma have significantly improved and are now comparable to other myeloma types because of earlier diagnosis, novel therapies, and improved supportive care. This trial was registered at clinicaltrials.gov as # NCT01554852.
引用
- Agbuduwe C, Iqbal G, Cairns D, et al. Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials. Blood Adv. 2022. PMID: 35790108. doi:10.1182/bloodadvances.2022007608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。